Our goal at OGene is to integrate early cancer screening into routine medical care programs, helping to provide navigation for the cancer patient’s cure process.
About Us
History
OGene Biotech Co. was established by Dr. Amin Kerachian in September 2015. Since then, OGene has been motivated by a desire to establish a better cancer detection method by liquid biopsy. We have executed exceptional development within the improvement of OColon and OKras, our blood-based tests for colorectal cancer diagnosis.
Dr. Amin Kerachian received his M.D. degree from Mashhad University of Medical Sciences (MUMS), Iran in 1998 and a Ph.D. in Human Genetics from McGill University and McGill University Health Center (MUHC), Canada in 2009. He completed two postdoc fellowships from the MUHC and MUMS. He then worked as a Scientific Director at Reza Radiotherapy and Oncology Center and served as a professor at Mashhad University in Iran.
Dr. Amin Kerachian
Liquid biopsy has the potential to provide minimally invasive and rapid results, contributing to the eradication of malignant cancers.
By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in liquid biopsy cancer detection. At OGene, we have the intention, tools, and expertise to not only reach our goals but to accomplish them to save lives.